tbuckley/cabot-search huggingface dataset:
Lactation Duration and Progression to Diabetes in Women Across the Childbearing Years
Authors: Erica P. Gunderson, Cora E. Lewis, Ying Lin, Mike Sorel, Myron Gross, Stephen Sidney, David R. Jacobs, James M. Shikany, Charles P. Quesenberry
Journal: JAMA Internal Medicine (2018)

<h3>Importance</h3> Lactation duration has shown weak protective associations with incident diabetes (3%-15% lower incidence per year of lactation) in older women based solely on self-report of diabetes, studies initiated beyond the reproductive period are vulnerable to unmeasured confounding or reverse causation from antecedent biochemical risk status, perinatal outcomes, and behaviors across the childbearing years. <h3>Objective</h3> To evaluate the association between lactation and progression to diabetes using biochemical testing both before and after pregnancy and accounting for prepregnancy cardiometabolic measures, gestational diabetes (GD), and lifestyle behaviors. <h3>Design, Setting, and Participants</h3> For this US multicenter, community-based 30-year prospective cohort study, there were 1238 women from the Coronary Artery Risk Development in Young Adults (CARDIA) study of young black and white women ages 18 to 30 years without diabetes at baseline (1985-1986) who had 1 or more live births after baseline, reported lactation duration, and were screened for diabetes up to 7 times during 30 years after baseline (1986-2016). <h3>Exposures</h3> Time-dependent lactation duration categories (none, &gt;0 to 6 months, &gt;6 to &lt;12 months, and ≥12 months) across all births since baseline through 30 years. <h3>Main Outcomes and Measures</h3> Diabetes incidence rates per 1000 person-years and adjusted relative hazards (RH) with corresponding 95% CIs, as well as proportional hazards regression models adjusted for biochemical, sociodemographic, and reproductive risk factors, as well as family history of diabetes, lifestyle, and weight change during follow-up. <h3>Results</h3> Overall 1238 women were included in this analysis (mean [SD] age, 24.2 [3.7] years; 615 black women). There were 182 incident diabetes cases during 27 598 person-years for an overall incidence rate of 6.6 cases per 1000 person-years (95% CI, 5.6-7.6); and rates for women with GD and without GD were 18.0 (95% CI, 13.3-22.8) and 5.1 (95% CI, 4.2-6.0), respectively (<i>P</i>for difference &lt; .001). Lactation duration showed a strong, graded inverse association with diabetes incidence: adjusted RH for more than 0 to 6 months, 0.75 (95% CI, 0.51-1.09); more than 6 months to less than 12 months, 0.52 (95% CI, 0.31-0.87), and 12 months or more 0.53 (0.29-0.98) vs none (0 days) (<i>P</i>for trend = .01). There was no evidence of effect modification by race, GD, or parity. <h3>Conclusions and Relevance</h3> This study provides longitudinal biochemical evidence that lactation duration is independently associated with lower incidence of diabetes. Further investigation is required to elucidate mechanisms that may explain this relationship.
The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study
Authors: Briony Larance, Timothy Dobbins, Amy Peacock, Robert Ali, Raimondo Bruno, Nicholas Lintzeris, Michael Farrell, Louisa Degenhardt
Journal: The Lancet Psychiatry (2018)
Antibiotic Use In Patients With Chronic Rhinosinusitis, With and Without Bronchiectasis, After Functional Endoscopic Sinus Surgery
Authors: Raul S. Villarreal, Whitney W. Stevens, Robert P. Schleimer, Bruce K. Tan, Robert C. Kern, Leslie C. Grammer, David B. Conley, Kevin C. Welch, Stephanie S. Smith, Anju T. Peters
Journal: Journal of Allergy and Clinical Immunology (2018)
Elevated levels of β6 integrin and alpha smooth actin positive microparticles in nasal lavage fluid in chronic rhinosinusitis with nasal polyps: a potential biomarker of epithelial-mesenchymal transition in the pathophysiology of polyp recurrence
Authors: Toru Takahashi, Atsushi Kato, Sergejs Berdnikovs, Whitney W. Stevens, Lydia A. Suh, James E. Norton, Roderick G. Carter, Kathleen E. Harris, Anju T. Peters, Kathryn E. Hulse, Leslie C. Grammer, Kevin C. Welch, Stephanie Shintani-Smith, Bruce K. Tan, David B. Conley, Robert C. Kern, Robert P. Schleimer
Journal: Journal of Allergy and Clinical Immunology (2018)
Maryland’s All-Payer Health Reform—A Promising Work in Progress
Authors: Joshua M. Sharfstein, Elizabeth A. Stuart, Joseph Antos
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Correction to: Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience
Authors: Perry G. Ridge, Celeste M. Karch, Simon Hsu, Ivan Arano, Craig C. Teerlink, Mark T. W. Ebbert, Josue D. Gonzalez Murcia, James M. Farnham, Anna R. Damato, Mariet Allen, Xue Wang, Oscar Harari, Victoria M. Fernandez, Rita Guerreiro, Jose Bras, John Hardy, Ronald Munger, Maria Norton, Celeste Sassi, Andrew Singleton, Steven G. Younkin, Dennis W. Dickson, Todd E. Golde, Nathan D. Price, Nilüfer Ertekin-Taner, Carlos Cruchaga, Alison M. Goate, Christopher Corcoran, JoAnn Tschanz, Lisa A. Cannon-Albright, John S. K. Kauwe
Journal: Genome Medicine (2018)

The original version of this article [1] unfortunately contained a typographical error. The 'Alzheimer's Disease Neuroimaging Initiative' was erroneously included as 'Alzheimer's Disease Neuroimaging Initative' in the author list of the article.
The Homeotic Protein SIX3 Suppresses Carcinogenesis and Metastasis through Recruiting the LSD1/NuRD(MTA3) Complex
Authors: Yu Zheng, Yi Zeng, Rongfang Qiu, Ruiqiong Liu, Wei Huang, Yongqiang Hou, Shuang Wang, Shuai Leng, Dandan Feng, Yang Yang, Yan Wang
Journal: Theranostics (2018)

The homeodomain transcription factor SIX3 was recently reported to be a negative regulator of the Wnt pathway and has an emerging role in cancer. However, how SIX3 contributes to tumorigenesis and metastasis is poorly understood.We employed affinity purification and mass spectrometry (MS) to identify the proteins physically associated with SIX3. Genome-wide analysis of the SIX3/LSD1/NuRD(MTA3) complex using a chromatin immunoprecipitation-on-chip approach identified a cohort of target genes including WNT1 and FOXC2, which are critically involved in cell proliferation and epithelial-to-mesenchymal transition. Also, we used flow cytometry, growth curve analysis, EdU incorporation assay, colony formation assays, trans-well invasion assays, immunohistochemical staining and in vivo bioluminescence assay to investigate the function of SIX3 in tumorigenesis.We demonstrate that the SIX3/LSD1/NuRD(MTA3) complex inhibits carcinogenesis in breast cancer cells and suppresses metastasis in breast cancer. SIX3 expression is downregulated in various human cancers and high SIX3 is correlated with improved prognosis.Our study revealed an important mechanistic link between the loss of function of SIX3 and tumor progression, identified a molecular basis for the opposing actions of MTA1 and MTA3, and may provide new potential prognostic indicators and targets for cancer therapy.
EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation
Authors: Denise Peker, Samara Roman-Holba, Yuri Kwon, Jennifer Gordetsky, Amitkumar Mehta, Andres Forero, Luciano J. Costa, Vishnu Reddy, Yang Yang, Balabhadrapatruni VSK Chakravarthi, Sooryanarayana Varambally
Journal: Blood (2016)
Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse
Authors: Leo Rasche, Carolina D. Schinke, Daisy Alapat, Grant Gershner, Sarah K Johnson, Sharmilan Thanendrarajan, Joshua Epstein, Frits van Rhee, Maurizio Zangari, James E McDonald, Rohan Samant, Edgardo Angtuaco, Brian A Walker, Bart Barlogie, Faith E. Davies, Gareth J. Morgan, Niels Weinhold
Journal: Blood (2017)
Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis
Authors: Kavish R. Patidar, Le Kang, Jasmohan S. Bajaj, Daniel Carl, Arun J. Sanyal
Journal: Hepatology (2018)

Current approaches to determine the cause of acute kidney injury (AKI) in patients with cirrhosis are suboptimal. The aim of this study was to determine the utility of fractional excretion of urea (FEUrea) for the differential diagnosis of AKI in patients with cirrhosis. A retrospective analysis was performed in patients (n = 50) with cirrhosis and ascites admitted with AKI. Using adjudicated etiology assessment as the reference standard, receiver operating curves and optimal cutoff, sensitivity (Sn), and specificity (Sp) for the diagnosis of prerenal azotemia (PRA), type 1 hepatorenal syndrome (HRS), and acute tubular necrosis (ATN) were derived. Validation was performed in an independent cohort (n = 50) and by bootstrap analysis. The causes of AKI (derivation:validation cohorts) were: PRA 21:21, HRS 18:15, and ATN 11:14. Median FEUrea was statistically different across all etiologies of AKI in the derivation cohort (PRA 30.1 vs. HRS 20.2 vs. ATN 43.6; P < 0.001) and validation cohort (PRA 23.1 vs. HRS 13.3 vs. ATN 44.7; P < 0.001). The area underneath the curve (cutoff, Sn/Sp) for FEUrea was 0.96 (33.4, 85/100) for ATN versus non‐ATN, 0.87 (28.7, 75/83) for HRS versus non‐HRS, and 0.81 (21.6, 90/61) for PRA versus HRS. When applied to the validation cohort, Sn/Sp were maintained for ATN versus non‐ATN (93/97), HRS versus non‐HRS (100/63), and for PRA versus HRS (67/80). After bootstrapping, Sn/Sp for FEUrea in the ATN versus non‐ATN, HRS versus non‐HRS, and PRA versus HRS was 88/96, 63/97, and 55/87, respectively. Conclusion: FEUrea is a promising tool for the differential diagnosis of AKI in patients with cirrhosis. (Hepatology 2018;68:224‐233)
A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia
Authors: Yali Xu, Joseph P. Milazzo, Tim D.D. Somerville, Yusuke Tarumoto, Yu-Han Huang, Elizabeth L. Ostrander, John E. Wilkinson, Grant A. Challen, Christopher R. Vakoc
Journal: Cancer Cell (2018)
Pulmonary Innate Lymphoid Cell Responses During Rhinovirus-Induced Asthma Exacerbations
Authors: Jaideep Dhariwal, Aoife Cameron, Ernie Wong, Belen Trujillo-torralbo, Ajerico Del rosario, Eteri Bakhsoliani, Malte Paulsen, David Jackson, Trevor T. Hansel, Michael Edwards, David Cousins, Ross P. Walton, Sebastian L. Johnston
Journal: Journal of Allergy and Clinical Immunology (2018)
Patterning of the hepato‐pancreatobiliary boundary by BMP reveals heterogeneity within the murine liver bud
Authors: Amrita Palaria, Jesse R. Angelo, Taylor M. Guertin, Jesse Mager, Kimberly D. Tremblay
Journal: Hepatology (2018)

During development, the endoderm initiates organ‐restricted gene expression patterns in a spatiotemporally controlled manner. This process, termed induction, requires signals from adjacent mesodermal derivatives. Fibroblast growth factor (FGF) and bone morphogenetic protein (BMP) emanating from the cardiac mesoderm and the septum transversum mesenchyme (STM), respectively, are believed to be simultaneously and uniformly required to directly induce hepatic gene expression from the murine endoderm. Using small molecule inhibitors of BMP signals during liver bud induction in the developing mouse embryo, we found that BMP signaling was not uniformly required to induce hepatic gene expression. Although BMP inhibition caused an overall reduction in the number of induced hepatoblasts, the STM‐bounded posterior liver bud demonstrated the most severe loss of the essential hepatic transcription factor, hepatocyte nuclear factor 4‐α (HNF4α), whereas the sinus venosus–lined anterior liver bud was less affected. We found that the posterior liver bud progenitors were anteriorly displaced and aberrantly activated pancreatobiliary markers, including sex‐determining region Y‐box 9 (SOX9). Additionally, we found that ectopically expressed SOX9 inhibited HNF4α and that BMP was indirectly required for hepatoblast induction. Finally, because previous studies have demonstrated that FGF signals are essential for anterior but not posterior liver bud induction, we examined synchronous BMP and FGF inhibition and found this led to a nearly complete loss of hepatoblasts. Conclusion: BMP signaling is required to maintain the hepato‐pancreatobiliary boundary, at least in part, by indirectly repressing SOX9 in the hepatic endoderm. BMP and FGF signals are each required for the induction of spatially complementary subsets of hepatoblasts. These results underscore the importance of studying early inductive processes in the whole embryo. (H epatology 2018;68:274‐288).
A Role for B Cells in Organic Dust Induced Lung Injury
Authors: Jill A. Poole, Ted R. Mikuls, Michael J. Duryee, Kristi J.J. Warren, Todd A. Wyatt, Amy J. Nelson, Debra J. Romberger, William W. West, Geoffrey Thiele
Journal: Journal of Allergy and Clinical Immunology (2018)
Exome Sequencing in Venous Thromboembolic Disease Identifies Excess Mutation Burden in PROS1, PROC, SERPINC1 and STAB2
Authors: Karl C. Desch, Ayse Bilge Ozel, Matt Halvorsen, Paula M. Jacobi, Marine Germain, David Alexandre Tregouet, Pieter H. Reitsma, David Goldstein, David Ginsburg
Journal: Blood (2016)
Prognostic benefit of the addition of an electroencephalographic (EEG) index to the MELD score: the MELD-EEG.
Authors: Sara Montagnese, M De Rui, Sami Schiff, G Spinelli, Francesca Campagna, Paolo Angeli, Umberto Cillo, G Zanus, Angelo Gatta, G Garcia Tsao, Piero Amodio, Carlo Merkel
Journal: Hepatology (2012)
Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Authors: K. J. Mason, M. Lunt, H. J. Hunter, Z. K. Jabbar-Lopez, B. Kirby, C. E. Kleyn, S. Kreppel, K. McElhone, N. J. Reynolds, R. B. Warren, C. E. M. Griffiths
Journal: British Journal of Dermatology (2017)
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
Authors: David Fitchett, Silvio E. Inzucchi, John M. Lachin, Christoph Wanner, Philippe van de Borne, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Jyothis T. George, Bernard Zinman
Journal: Journal of the American College of Cardiology (2018)

Diabetes is associated with a significant decrease in life expectancy [(1)][1]. In the EMPA-REG OUTCOME trial ([NCT01131676][2]), empagliflozin given in addition to standard of care reduced the risk of cardiovascular death by 38% (hazard ratio [HR]: 0.62; 95% confidence interval [CI]: 0.49 to 0.77;
Abstract 20418: Racial Differences in Outcomes With Dabigatran and Rivaroxaban versus Warfarin in Medicare Population With Atrial Fibrillation
Authors: Rajesh Kabra, Mary Vaughan Sarrazin
Journal: Circulation (2016)

Introduction: Dabigatran and rivaroxaban were approved for stroke prevention in atrial fibrillation (AF) based on clinical trials which included very few black patients. Hypothesis: To assess if da...
Toxicity of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis.
Authors: Kathryn Cunningham Hourdequin, William Lewis Schpero, Breanne Lee Piazik, Dorothy R McKenna, Robin Joyce Larson
Journal: Journal of Clinical Oncology (2012)

6013 Background: Because weight-based chemotherapy calculations can be very large in obese patients, oncologists often empirically reduce doses due to fear of excess toxicity. The resulting underdosing may negatively impact survival. We performed a systematic review and meta-analysis to determine whether, among adults receiving chemotherapy dosed by actual body weight (ABW), obese patients experience differing toxicity or survival compared to normal-weight patients. Methods: We searched MEDLINE, Cochrane Library, Web of Science, and ClinicalTrials.gov through October 2011 and reviewed reference lists. We included studies that compared outcomes of obese versus normal-weight adults receiving chemotherapy dosed according to ABW (+/- 5% variability). Studies followed subjects for at least one cycle of chemotherapy and reported at least one pre-specified outcome. Two authors independently abstracted data from eligible studies. We used random effects models to pool odds ratios (OR) for hematologic and non-hematologic toxicities. We summarized survival qualitatively. Results: Of 3,921 studies, five met inclusion criteria, for a total of 6,877 subjects. Based on three studies, Grade 3/4 hematologic toxicity occurred less often in obese patients than normal-weight patients (OR 0.68, 95% CI 0.51-0.89, I 2 =29%). A fourth study comparing leukocyte nadirs had variable results depending on the regimen, dosing, and patient co-morbidities. Based on two studies, Grade 3/4 non-hematologic toxicity occurred less often in obese patients than normal-weight patients (OR 0.74, 95% CI 0.63-0.87, I 2 =0%). A third study found rates of infection did not significantly differ. Three of four studies reported reduced overall survival in obese patients (statistical significance not reported). Conclusions: Contrary to common belief, obese patients receiving chemotherapy based on ABW appear to have lower rates of both hematologic and non-hematologic toxicities compared to normal-weight patients. These results do not support the practice of empiric dose reduction in obese patients. Further research should explore etiologies for the reduced survival in this group.
Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD
Authors: Ryan D. Cassaday, Philip A. Stevenson, Brent L. Wood, Pamela S. Becker, Paul C. Hendrie, Brenda M. Sandmaier, Jerald L. Radich, Andrei R. Shustov
Journal: American Journal of Hematology (2018)

Abstract HyperCVAD is a commonly‐used regimen for adults with newly‐diagnosed acute lymphoblastic leukemia (ALL). However, relatively little is known about the application of minimal residual disease (MRD) detection with this treatment. To address this, we studied 142 adults with ALL treated with hyperCVAD over a 10‐year period who had MRD assessed by either multi‐parameter flow cytometry or (for patients with Philadelphia chromosome positive ALL) reverse transcriptase polymerase chain reaction for the BCR‐ABL1 translocation. In a multivariate analysis, patients who achieved MRD negativity (MRD Neg ) at any point had significantly better overall survival (OS; hazard ratio [HR] 0.43; P = .01) and event‐free survival (EFS; HR 0.27; P &lt; .01). Of 121 patients with MRD assessed at various points within 90 days of starting hyperCVAD, 50% ( n = 61) had achieved MRD Neg . Among those that became MRD Neg , the median time to MRD Neg was 68 days. Time to MRD Neg was significantly associated with EFS ( P = .009), but not OS ( P = .19), implying increasingly better EFS the earlier MRD Neg is achieved. These data add to our understanding of MRD assessment during treatment with hyperCVAD, aide clinicians with predicting relapse risk, and provide additional historical data on which future clinical trials can be designed.
Abstract 17054: Genes Associated With Inotrope Requirements in Children Undergoing Tetralogy of Fallot Repair
Authors: Stephen Lee, Ashok K Manickaraj, Danny Lu, Roderick Yao, Michelle A Chan-Seng-Yue, Peter Laussen, Steven Schwartz, Seema Mital
Journal: Circulation (2016)

Introduction:  Inotropes are used to prevent or treat postoperative low cardiac output syndrome. Common variants in adrenergic (ADR) signaling genes can influence inotrope response. We investigated association of both common and rare variants in ADR signaling genes with inotrope requirements in tetralogy of Fallot (TOF) patients undergoing surgical repair.   Methods:  Of 276 TOF eligible patients, 120 with complete 72 hour post-operative data were analyzed. All common and rare (   Results:  Of 120 patients, 55 had high inotrope requirement (i.e. inotropes for >48hrs, doubling of dose, or initiation of additional inotrope). Mean CPB time was higher in the high-inotrope vs low inotrope group (128±58 vs 100±34 mins, p =0.002), as was ACC time (88±35 vs 76±25 mins, p=0.038). After adjusting for CPB and ACC time, high inotrope group had lower 24 hour mean blood pressures (p PPP1R13B, PPP1R3F,  PPP1R3A ) belonged to the protein phosphatase-1 (PP1) family. PP1 is a critical negative regulator of Ca2+ cycling and contractility in cardiomyocytes and mediates inotropic response to β-adrenergic stimulation.   Conclusions:  There was considerable variability in inotrope requirements in children undergoing TOF repair. Variants in PP1 gene were associated with inotrope requirements. Genomic analysis on a larger cohort is underway to identify other pharmacogenetic variants that influence inotrope response. This may guide individualization of post-operative inotrope choices in the future.
Improvements In Individual Asthma Control Questionnaire (ACQ-5) Questions With Reslizumab In Patients With Inadequately Controlled Asthma and Elevated Blood Eosinophils: Pooled Analysis of Two Phase 3 Trials
Authors: Phillip E. Korenblat, Mirna McDonald, Margaret Garin
Journal: Journal of Allergy and Clinical Immunology (2018)